Skip to main content
padlock icon - secure page this page is secure

Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents

Buy Article:

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Isoliquiritigenin (2’,4’,4-trihydroxychalcone, ISL) is one of the most important chalcone compounds which is mainly derived from licorice root and many other plants. It exhibits a remarkable range of potent biological and pharmacological activities such as antioxidative, antitumor, antiaging, anti-inflammatory, anti-diabetic activities, etc. Numerous research teams have demonstrated that ISL posseses the ability to carry out antigrowth and proliferation in various cancer cells in vitro and in vivo. Meanwhile, the underlying mechanisms of ISL that inhibit cancer cell proliferation have not been well explored. However, the poor bioavailability and low water-soluble limit its clinical application. This review aims at providing a comprehensive overview of the pharmacology antitumor activity of ISL and its mechanisms in different malignancy especially in breast cancer cell line and summarize developments of formulation utilized to overcome the barrier between its delivery characteristics and application in clinics over the past 20 years.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Isoliquiritigenin; antitumor; breast cancer; formulation; mechanisms; signaling pathway

Affiliations: State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, People’s Republic of China.

Appeared or available online: March 8, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more